Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesotheliomas in xenografts

BACKGROUND: Malignant mesotheliomas (MMs) are chemoresistant tumors related to exposure to asbestos fibers. The long latency period of MM (30-40 yrs) and heterogeneity of tumor presentation make MM difficult to diagnose and treat at early stages. Currently approved second-line treatments following s...

詳細記述

保存先:
書誌詳細
主要な著者: Macura, Sherrill L, Steinbacher, Jeremy L, MacPherson, Maximilian B, Lathrop, Melissa J, Sayan, Mutlay, Hillegass, Jedd M, Beuschel, Stacie L, Perkins, Timothy N, Spiess, Page C, van der Vliet, Albert, Butnor, Kelly J, Shukla, Arti, Wadsworth, Marilyn, Landry, Christopher C, Mossman, Brooke T
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2013
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3846908/
https://ncbi.nlm.nih.gov/pubmed/24024776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-400
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料